A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma

Refractory pheochromocytoma and paraganglioma (PPGL) have a poor prognosis and the treatment strategy remains to be established. This multi-institutional phase I study was performed to determine the safety, dose-limiting toxicity (DLT), and efficacy of [(131)I]-meta-iodobenzylguanidine ((131)I-mIBG)...

Descripción completa

Detalles Bibliográficos
Autores principales: Wakabayashi, Hiroshi, Inaki, Anri, Yoshimura, Kenichi, Murayama, Toshinori, Imai, Yasuhito, Higuchi, Tetsuya, Jinguji, Megumi, Shiga, Tohru, Kinuya, Seigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527850/
https://www.ncbi.nlm.nih.gov/pubmed/31110198
http://dx.doi.org/10.1038/s41598-019-43880-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527850/
https://www.ncbi.nlm.nih.gov/pubmed/31110198
http://dx.doi.org/10.1038/s41598-019-43880-6

Ejemplares similares